>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>PI-3065

PI-3065

Catalog No.GC15310

PI-3065는 PI3K p110δ의 강력한 억제제이며 IC50 및 Ki 값이 5nM 및 1.5nM이고 IC50이 910, 600, >10000nM인 p110α, p110β, p110γ에 대해 덜 강력한 활성을 나타냅니다.

Products are for research use only. Not for human use. We do not sell to patients.

PI-3065 Chemical Structure

Cas No.: 955977-50-1

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$81.00
재고 있음
5mg
US$75.00
재고 있음
10mg
US$107.00
재고 있음
50mg
US$308.00
재고 있음
100mg
US$443.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

PI-3065 is a small molecule and selective inhibitor of p110δkinase with an Ki value of 1.5nM and IC50 value of 5nM [1].

PI-3065 has been reported to selectively inhibit p110δkinase with Ki values of 15nM, 110nM, 130nM and 940nM, IC50 values of 5nM, 91nM, 600nM and >10000nM for p110δ, p110α, p110β and p110γ, respectively. In addition, PI-3065 has been revealed to inhibit 4T1 tumour growth and metastasis. PI-3065 has also noted to prolong survival and reduce the incidence of macroscopic metastases and other disease-associated pathologies [1].

References:
[1] Ali K1, Soond DR2, Pi?eiro R1, Hagemann T3, Pearce W4, Lim EL5, Bouabe H5, Scudamore CL6, Hancox T7, Maecker H8, Friedman L8, Turner M5, Okkenhaug K9, Vanhaesebroeck B1. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11. doi: 10.1038/nature13444. Epub 2014 Jun 11.

리뷰

Review for PI-3065

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PI-3065

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.